Table 4.

Interference and potential effects of certain substances on continuous glucose monitoring of glucoses

CGM system	Methodology	Interference	No interference	Potential interference based on methodology (106, 137)
Medtronic Guardian 3 (122, 126)	GO	Acetaminophen Ethanol/Wine Albuterol Lisinopril Atenolol Atorvastatin Ascorbic acid	Hydrochlorothiazide, losartan	Anemia Ascorbic acid Hypoxia hypothermia hypotension Mannitol Uric acid (> 20 mg/dL) Polycythemia oxygen therapyHypertriglyceridemia Bilirubin > 54 mg/dL
Dexcom G6 (127)	GO + Perm-selective membrane coating		Acetaminophen (up to 1000 mg every 6 h)
FreeStyle Libre 14 d (122, 138)	GO + Redox sensing membrane	Ascorbic acid Salicylic acid	Acetaminophen, methyldopa, tolbutamide
Senseonics Eversense (128)	Nonenzymatic electrochemical fluorescent-based polymer	Tetracycline Mannitol	Acetaminophen Ascorbic acid Amoxicillin Creatinine Heparin Levofloxacin Urea Galactose Maltose Lactose Xylose Sugar alcohols (eg, sweeteners) At therapeutic doses: salicylic acid lactate L-DOPA Piroxicam

Abbreviation: CGM, continuous glucose monitoring; GO, glucose oxidase-based.